<PAGE>
================================================================================


                        SECURITES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                   FORM 10-QSB

[X]      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
         ACT OF 1934

                FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 28, 2002

                                       OR

[ ]      TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT



                          COMMISSION FILE NUMBER 0-9478
                           __________________________

                           SPECTRUM LABORATORIES, INC.
             (Exact name of Registrant as specified in its charter)

             DELAWARE                                   95-4718363
   (State or other jurisdiction             (I.R.S. Employer Identification No.)
of incorporation or organization)


           18617 BROADWICK STREET, RANCHO DOMINGUEZ, CALIFORNIA 90220
               (Address of principal executive offices) (zip code)

       Registrant's telephone number, including area code: (310) 885-4600

Indicate by check mark whether the issuer (1) filed all reports required to be
filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes
[X] No [ ]

 Number of shares of Common Stock outstanding as of October 31, 2002: 5,312,468


                  TRANSITIONAL SMALL BUSINESS DISCLOSURE FORMAT

                                 YES [ ] NO [X]

================================================================================

<PAGE>


                                                                            Page
                                                                            ----
Part I - FINANCIAL INFORMATION

Item 1.   Financial Statements
          Consolidated Balance Sheet as of September 28, 2002                 3
          Consolidated Statements of Income for the Three and Nine
            Months Ended September 28, 2002 and September 29, 2001            4
          Consolidated Statements of Cash Flows for the Nine Months
            Ended September 28, 2002 and September 29, 2001                   5
          Notes to Consolidated Statements                                    6

Item 2.   Management's Discussion and Analysis of Financial Condition
            and Results of Operations                                         8

Item 3.   Controls and Procedures                                            10


Part II - OTHER INFORMATION

Item 1.   Legal Proceedings                                                  10
Item 2.   Changes in Securities                                              10
Item 3.   Defaults Upon Senior Securities                                    10
Item 4.   Submission of Matters to a Vote of Security Holders                10
Item 5.   Other Information                                                  10
Item 6.   Exhibits and Reports on Form 8-K                                   11
Signature                                                                    13
Certifications      Certifications - Chief Financial Officer and Chief
                         Executive Officer                                   14





                                       2
<PAGE>


Part I.  FINANCIAL INFORMATION

Item 1.  Financial Statements



                           SPECTRUM LABORATORIES, INC.
                           CONSOLIDATED BALANCE SHEET
                            AS OF SEPTEMBER 28, 2002
                    (DOLLARS IN THOUSANDS, EXCEPT PAR VALUE)
                                   (UNAUDITED)


ASSETS
CURRENT ASSETS:
     Cash and cash equivalents                                        $   2,881
     Accounts receivable                                                  1,639
     Inventories                                                          1,848
     Prepaid expenses                                                       362
     Deferred taxes                                                         293
                                                                      ----------
     Total current assets                                                 7,023

EQUIPMENT AND LEASEHOLD IMPROVEMENTS                                      2,851
GOODWILL, not subject to amortization                                     1,122
DEFERRED TAXES                                                            1,662
PATENTS, subject to amortization, net of accumulated
   amortization of $106,000                                                 644
OTHER ASSETS                                                                 33
                                                                      ----------

     Total assets                                                     $  13,335
                                                                      ==========

LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
     Current maturities of long-term debt                             $     750
     Accounts payable                                                       607
     Accrued expenses and other current liabilities                         796
                                                                      ----------
     Total current liabilities                                            2,153

LONG-TERM DEBT, net of current maturities                                 1,125

MINORITY INTEREST                                                         1,755

STOCKHOLDERS' EQUITY:
     Common stock, $.01 par value,  25,000,000 shares authorized;
        5,312,468 shares issued and outstanding                              53
     Preferred stock, par value $.01; 10,000,000 shares authorized;
        none issued or outstanding                                           --
     Additional paid-in capital                                           8,476
     Accumulated deficit                                                   (227)
                                                                      ----------
     Total stockholders' equity                                           8,302
                                                                      ----------

     Total liabilities and stockholders' equity                       $  13,335
                                                                      ==========

See Notes to Consolidated Financial Statements.

                                       3
<PAGE>
<TABLE>

                           SPECTRUM LABORATORIES, INC.
                        CONSOLIDATED STATEMENTS OF INCOME
                  (IN THOUSANDS, EXCEPT FOR PER SHARE AMOUNTS)
                                   (UNAUDITED)

<CAPTION>

                                            Three Months Ended     Nine Months Ended
                                           --------------------   --------------------
                                             Sep 28.    Sep 29,    Sep 28,    Sep 29,
                                              2002       2001       2002       2001
                                           ---------  ---------   ---------  ---------
<S>                                        <C>        <C>         <C>        <C>
NET SALES                                  $  3,176   $  3,112    $  9,768   $  9,595

COSTS AND EXPENSES
    Cost of sales                             1,605      1,758       5,220      5,311
    Selling, general and administrative       1,054      1,008       3,081      3,176
    Research and development                    178        190         539        521
    Other expense, primarily interest            13          2          43         22
                                           ---------  ---------   ---------  ---------

    Total costs and expenses                  2,850      2,958       8,883      9,030

Income before provision for income taxes        326        154         885        565

Provision for income taxes                      131         62         354        226
                                           ---------  ---------   ---------  ---------

     Net income                            $    195   $     92    $    531   $    339
                                           =========  =========   =========  =========


Earnings per share:
    Basic                                  $   0.04   $   0.02    $   0.10   $   0.06
                                           =========  =========   =========  =========
    Diluted                                $   0.04   $   0.02    $   0.10   $   0.06
                                           =========  =========   =========  =========

Weighted average shares outstanding:
    Basic                                     5,312      5,312       5,312      5,312
                                           =========  =========   =========  =========
    Diluted                                   5,357      5,484       5,368      5,455
                                           =========  =========   =========  =========

</TABLE>

See Notes to Consolidated Financial Statements.

                                       4
<PAGE>
<TABLE>


                           SPECTRUM LABORATORIES, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
           NINE MONTHS ENDED SEPTEMBER 28, 2000 AND SEPTEMBER 29, 2001
                                 (IN THOUSANDS)
                                   (UNAUDITED)
<CAPTION>

                                                                          2002       2001
                                                                        --------   --------
<S>                                                                     <C>        <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income                                                              $   531    $   339
Adjustments to reconcile net income to net cash
   provided by operating activities:
  Depreciation and amortization                                             502        544
  Noncash compensation                                                       18         22
  Change in working capital components:
    Decrease (Increase) in accounts receivables                              50         (8)
    (Increase) Decrease in inventories                                     (201)        95
    (Increase) Decrease in prepaid expenses                                (227)        46
    Increase in accounts payable                                            177         40
    Increase in accrued expenses                                            296        189
                                                                        --------   --------
     NET CASH PROVIDED BY OPERATING ACTIVITIES                            1,146      1,267
                                                                        --------   --------

CASH FLOWS FROM INVESTING ACTIVITIES:
  Acquisitions of equipment and leasehold improvements                     (459)      (604)
   Acquisition of patents                                                  (250)      (500)
                                                                        --------   --------
     NET CASH (USED IN) INVESTING ACTIVITIES                               (709)    (1,104)
                                                                        --------   --------

CASH FLOWS FROM FINANCING ACTIVITIES:
  Principal payments of long-term debt                                     (583)      (616)
  Loan Proceeds                                                              --        225
                                                                        --------   --------

     NET CASH (USED IN) FINANCING ACTIVITIES                               (583)      (391)
                                                                        --------   --------

     NET DECREASE IN CASH AND CASH EQUIVALENTS                             (146)      (228)

CASH AND CASH EQUIVALENTS, beginning of period                            3,027      1,121
                                                                        --------   --------

CASH AND CASH EQUIVALENTS, end of period                                $ 2,881    $   893
                                                                        ========   ========

</TABLE>

See Notes to Consolidated Financial Statements.

                                       5
<PAGE>

NOTES TO CONSOLIDATED STATEMENTS

Note 1

Basis of Presentation - The accompanying unaudited financial statements
consolidate the accounts of Spectrum Laboratories, Inc. and its subsidiaries,
SLI Acquisition Corp., Spectrum Europe B.V. and Spectrum Chromatography
(collectively, the Company). All significant intercompany transactions have been
eliminated in consolidation. In the opinion of management, the accompanying
unaudited interim consolidated financial statements contain all adjustments
(consisting only of normal recurring adjustments) necessary to present fairly
the financial position of the Company as of September 28, 2002 and the results
of its operations for the three months and nine months ended September 28, 2002
and September 29, 2001 and its statement of cash flows for the nine months ended
September 28, 2002 and September 29, 2001. Certain information and footnote
disclosures normally included in the financial statements have been condensed or
omitted pursuant to rules and regulations of the Securities and Exchange
Commission, although the Company believes that the disclosures in the unaudited
interim financial statements are adequate to make the information presented not
misleading.

New Accounting Standards - In June 2001, the Financial Accounting Standards
Board (FASB) issued Statement of Financial Accounting Standards No. 142,
GOODWILL AND OTHER INTANGIBLE ASSETS (SFAS No. 142). SFAS No. 142 addresses
financial accounting and reporting for acquired goodwill and other intangible
assets and was effective for the Company beginning December 30, 2001. Upon
adoption of SFAS 142, management has determined there is one reporting unit and
tested the carrying value of goodwill for any impairment losses and has
determined that no impairment exists. Also in accordance with SFAS 142, the
Company has not recorded amortization expense with respect to goodwill during
the three and nine month periods ended September 28, 2002, while approximately
$21,000 and $62,000 of amortization expense was recorded during the three and
nine month periods ended September 29, 2001. Reported net income would be
increased by $12,000 and $37,000 for the three and nine month periods ended
September 29, 2001, net of related tax effect, to $104,000 and $376,000,
respectively had goodwill been accounted for in accordance with SFAS 142. There
would have been no affect on basic or diluted earnings per share for the three
months ended September 29, 2001. Basic and diluted earnings per share for the
nine months ended September 29, 2001 would both increase to by $.01 per to share
$.07 per share.

In August 2001 the FASB issued Statement of Financial Accounting Standards No.
144, ACCOUNTING FOR THE IMPAIRMENT OR DISPOSAL OF LONG-LIVED ASSESTS (SFAS No.
144). SFAS No. 144 addresses the financial accounting and reporting for the
impairment or disposal of long-lived assets. The Company has adopted SFAS 144
during the first quarter of 2002 with no material impact on the consolidated
financial statements.

Patents - The Company has acquired patents, which are amortized over their
respective lives. Management evaluates the usefulness of these patents annually
in determining any potential impairment. Amortization, with respect to these
patents, for the three and nine month periods ended September 28, 2002 was
approximately $15,000 and $45,000, respectively. Estimated amortization expense
for the next five years is approximately $60,000 annually, all of which relates
to these patents.

Note 2 - Inventories

Inventories are stated at the lower of cost, determined using the first-in,
first-out method, or net realizable value and are composed of the following (in
thousands):

          Raw materials                           $   1,026
          Work in process                               175
          Finished goods                                647
                                                  ----------
                                                  $   1,848
                                                  ==========


                                       6
<PAGE>

Note 3 - Earnings per Share

Basic earnings per share is computed by dividing the net income attributable to
the common stockholders by the weighted average number of common shares
outstanding during the period. There is no adjustment in the net income
attributable to common stockholders. Diluted earnings per share reflect the
potential dilution that could occur from common shares issuable through stock
options (44,493 and 55,557 shares in the year 2002 three and nine month periods
respectively, and 171,136 and 142,710 in the year 2001 three and nine month
periods, respectively).

Note 4 - Income Taxes

In assessing the realizability of deferred tax assets, management has estimated
that it is likely that approximately $1,500,000 will not be realized. This
valuation allowance represents a portion of net operating loss carryforwards
attained through a prior business acquisition. As further discussed below, tax
law limits the use of an acquired entity's net operating loss carryforwards to
subsequent taxable income of the consolidated entity. Management will continue
to evaluate the realizability of the deferred tax assets by assessing the need
for and amount of a valuation allowance.

At December 29, 2001, the Company had approximately $5.8 million in net
operating loss carryforwards for federal income tax purposes available to offset
future taxable income. Certain of these loss carryforwards are limited to
approximately $298,000 annually. Any unused net operating loss is carried
forward. As a result of the limitation discussed above, it is probable that
$4,500,000 of the Company's net operating loss will expire without utilization.
Loss carryforwards for tax purposes expire in amounts and by fiscal year as
follows: 2004 $1,600,000; 2005 $1,319,000; 2011 $20,000; 2012 $347,000; 2013
$776,000; 2022 to 2026 $299,000 per year; 2027 $275,000.

Note 5 - Product Group Information

The Company's product groups are based on specific product characteristics and
are grouped into laboratory products and operating room disposable products.
Laboratory products consist primarily of: (1) membranes used to concentrate,
separate and purify dissolved or suspended molecules that are sold primarily to
laboratories and (2) hollow fiber membrane devices that allow components
retained by a membrane to be concentrated including filters utilized for micro
and ultrafiltration separations that are sold to biotech and pharmaceutical
companies. Operating room disposable products consist primarily of sterile
plastic surgical drapes and cloth bandages that are sold primarily to hospitals.

Revenue by product group is as follows (in thousands):

                                          Three Months Ended  Nine Months Ended
                                          ------------------  ------------------
                                          Sept 28,  Sept 29,  Sept 28,  Sept 29,
                                            2002      2001      2002      2001
                                          --------  --------  --------  --------
Laboratory products                         2,733     2,655     8,534     8,252
Operating room disposable products            443       457     1,234     1,343
                                          --------  --------  --------  --------
                                          $ 3,176   $ 3,112   $ 9,768   $ 9,595
                                          ========  ========  ========  ========

Note 5 - Option Plan

The Company had two options plans referred to as the 1995 Option Plan and the
2000 Option Plan with 200,000 and 300,000 shares of common stock, respectively
reserved for option grants to key employees, directors and consultants. In July
2002, the shareholders' approved merging the 1995 Option Plan and the 2000
Option Plan into one plan to be referred to as the 2000 Option Plan (the "2000
Option Plan"). In addition, shareholders approved the number of shares available
to grant under the 2000 Option Plan by 100,000 to a total of 600,000. On July
15, 2002, the Board of Directors approved 225,000 stock option grants to two
employees. As of September 28, 2002, there were 483,100 options outstanding
under the 2000 Option Plan.


                                       7
<PAGE>

Item 2. Management's Discussion and Analysis of Financial Condition and Results
        of Operations

The following discussion should be read in conjunction with the Consolidated
Financial Statements of Spectrum Laboratories, Inc. and Notes thereto contained
elsewhere within this Report on Form 10-QSB. Except for the historical
information contained herein, the following discussion may contain
forward-looking statements that involve risks and uncertainties. The actual
future results of the Company could differ materially from those discussed here.
Factors that could cause or contribute to such differences include, but are not
limited to, those discussed in this report and those factors discussed in the
Company's Form 10-KSB for the year ended December 29, 2001 as filed with the
Securities and Exchange Commission and, from time to time, in the Company's
other reports on file with the Commission.

Summary of Significant Accounting Policies

Determining Impairment on Long-lived Assets - The Company recognizes impairment
losses for long-lived assets used in operations when indicators of impairment
are present and the undiscounted cash flows are not sufficient to recover the
assets' carrying amount. Management believes there has been no impairment of the
value of such assets.

Patents - The Company has acquired patents utilized within the various
manufacturing processes. These patents are amortized over their respective
lives, typically 17 years. Management believes there has been no impairment in
the value of these patents.

Accounting for Stock-based Compensation - The Company accounts for stock-based
employee compensation under the requirements of Accounting Principles Board
(APB) Opinion No. 25, which does not require compensation to be recorded if the
consideration to be received is at least equal to fair value at the measurement
date. Nonemployee stock-based transactions are accounted for under the
requirements of the Financial Accounting Standards Board's (FASB) Statement of
Financial Accounting Standards (SFAS) No. 123, ACCOUNTING FOR STOCK-BASED
COMPENSATION, which requires compensation to be recorded based on the fair value
of the securities issued or the services received, whichever is more reliably
measurable.

Results of Operations

Sales

Sales for the three month period ended September 28, 2002 ("third quarter")
increased $64,000 (2.1%) compared to the third quarter of 2001. Sales for
laboratory products increased $78,000 (2.9) while the operating room disposable
product group was $14,000 (3.1%) below third quarter 2001 revenues.
For the nine month period ended September 28, 2002 ("year to date") sales
increased $173,000 (1.8%) compared to 2001 year to date sales. Laboratory
product sales increased $282,000 (3.4%) compared to year to date sales in 2001
while sales for the operating room disposable product group was $109,000 (8.1%)
below 2001 year to date. The increase in the laboratory product sales was
primary related to a $199,000 (8.1%) increase in European sales.

Gross Margin

Gross Margin for the third quarter of 2002 was $1,571,000 (49.5%) versus the
third quarter of 2001 of $1,354,000 (43.5%). The increase in gross margin
percentage was due to product mix in the third quarter of 2002 and a positive
Euro exchange rate. In addition, 2001 year to date gross margin was negatively
impacted by an inventory adjustment. On a year to date basis gross margin was
$4,548,000 (46.6%), a 2% point margin improvement over of 2001 gross margin of
$4,284,000 (44.6%). The items, as noted in the quarterly gross margin
improvement were also the primary factors contributing to the year to date gross
margin improvement.

                                       8
<PAGE>

Selling, General & Administrative and Research & Developmental Expenses
("Expenses")

Expenses for the third quarter of 2002 were $1,232,000, an increase of $34,000
(2.8%) from the third quarter of 2001. The increase in expenditures was
attributable to the increase in advertising related expenditures partially
offset by reduced other expenditures as noted in the year to date commentary
below.

On a year to date basis, expenses were $3,620,000, a decrease of $77,000 (2.1%)
compared to the same period in 2001. The Company has distributed a significant
number of catalogs during 2002, as it historically issues a new catalog every 2
years, an industry practice. In addition the Company recently printed "The ABCs
of Filtration and BioProcessing for the Third Millennium" a 154 page brochure as
well as a 16 page quarterly newsletter "The Bioprocessor" both of which have and
will be distributed to customers. In compliance with the Statement of Position
93-7 - Reporting on Advertising Costs as issued by the American Institute of
Certified Public Accountants the Company is expensing costs associated with the
aforementioned items as distributed. Thus advertising related expenditures
totaled $257,000 on a year to date basis in 2002, an increase over the
comparable 2001 period by $183,000. More than offsetting this expenditure
increase were goodwill amortization decreasing $62,000, employee associated
compensation decreasing $43,000, consulting/contract services down $40,000 and
finally reduced net all other of $115,000.

Income before Taxes

The net of the above resulted in income before taxes in the third quarter of
2002 of $326,000 an increase of $172,000 (112%) over the third quarter of 2001.
On a year to date basis 2002 pre tax income was $885,000, an increase of
$320,000 (57%) versus 2001 year to date results.

Liquidity and Capital Resources

During the first nine months of fiscal 2002, the Company generated approximately
$1,146,000 of cash from operating activities. Cash from operating activities was
positively impacted by an increase in accrued expenses of $296,000 principally
attributable to income taxes, which were partially offset, by a $227,000
increase in prepaid expenses. The increase in prepaid expenses corresponds to
the above mentioned catalog and related brochures that totaled $112,000 and the
timing of rent, insurance and royalty payments resulting in an additional
increase of $84,000. The cash from operating activities was offset by $583,000
in bank loan payments, $250,000 relating to the acquisition of patents and
$459,000 for purchases of equipment and costs for leasehold improvements. This
resulted in a net decrease in cash for the period of approximately $146,000 to a
cash and cash equivalent balance at September 28, 2002 of $2,881,000.

Subsequent to September 28, 2002 the company did commit $105,000 for a license
relating to new software Spectrum has selected in order to operate its business
more efficiently. The actual software implementation will begin during the
second quarter of 2003 and the Company anticipates the conversion date will be
June 30, 2003. The total cost of the software implementation is currently
estimated at $350,000.

The Company is obligated under the terms of various operating lease agreements
for manufacturing, warehouse and office facilities. Certain of these leases
provide for rent escalation adjustments. Minimum future rental payments under
these operating lease agreements for the fourth quarter ending December 28, 2002
and the subsequent years ending December 31 are as follows: fourth quarter 2002
$119,000; 2003 $460,000; 2004 $341,000; and 2005 $186,000 (total $1,463,000).

The Company's management believes that cash on hand and cash expected to be
generated from operations will be sufficient to meet cash requirements for the
next twelve months.


                                       9
<PAGE>

Item 3.  Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures. The Company's Chief
Executive Officer and its Chief Financial Officer , after evaluating the
effectiveness of the Company's disclosure controls and procedures (as defined in
Securities Exchange Act of 1934 Rules 13a-14(c) and 15d-14(c) as of a date
within 90 days of the filing date of this quarterly report on Form 10-QSB (the
"Evaluation Date")), have concluded that as of the Evaluation Date, the
Company's disclosure controls and procedures were adequate and effective to
ensure that material information relating to the Company would be made known to
them by others within the Company, particularly during the period in which this
quarterly report on Form 10-QSB was being prepared.

(b) Changes in Internal Controls. There were no significant changes in the
Company's internal controls or in other factors that could significantly affect
the Company's disclosure controls and procedures subsequent to the Evaluation
Date, nor any significant deficiencies or material weaknesses in such disclosure
controls and procedures requiring corrective actions. As a result no corrective
actions were taken.



Part II.  OTHER INFORMATION

Item 1.  Legal Proceedings
          None

Item 2.  Change in Securities and Use of Proceeds
          None

Item 3.  Defaults Upon Senior Securities
          None

Item 4.  Submission of Matters to a Vote of Security Holders

         At the Company's fiscal 2002 Annual Meeting of Stockholders held on
         July 15, 2002 the following individuals constituting all of the members
         of the Board of Directors were elected. For each elected director, the
         results of the voting were:
<TABLE>
<CAPTION>

                                       Affirmative Votes     Negative Votes     Votes Withheld
                                       -----------------     --------------     --------------
<S>                                            <C>                    <C>                <C>
         Roy T. Eddleman                       4,320,128              0                  0
         Thomas V. Girardi, J.D.               4,320,128              0                  0
         Jay Henis, Ph. D.                     4,320,128              0                  0
         Walter J. Lack, J.D.                  4,320,128              0                  0
         Jack Whitescarver, Ph. D.             4,320,128              0                  0
</TABLE>

         The stockholders voted to ratify the selection of McGladrey & Pullen,
         LLP as the Company's independent accountants for the fiscal year ending
         2002, pending Board of Directors approval of audit quotation. The
         results of the voting of this proposal were 4,320,128 affirmative
         votes, 0 negative votes and no votes were withheld.

         The stockholders also approved merging the 1995 Option Plan and the
         2000 Option Plan into one plan to be referred to as the 2000 Option
         Plan. In addition, shareholders increased the number of shares
         available to grant under the 2000 Option Plan by 100,000 to a total of
         600,000. The results of the voting of this proposal were 4,320,128
         affirmative votes, 0 negative votes and no votes were withheld.

Item 5.  Other Information
          None



                                       10
<PAGE>

Item 6.  Exhibits and Reports on Form 8-K

(a)      Exhibits

Exhibit No.                         Description

3.1               Articles of Incorporation of Registrant (incorporated by
                  reference to Exhibit 4.1 filed with Registrant's Registration
                  Statement on Form S-2, Registration No. 2-68999)

3.2               Amendment to Article I of the Articles of Incorporation of
                  Registrant (incorporated by reference to Exhibit 3.2 filed
                  with Registrant's Report on Form 10-K for the fiscal year
                  ended December 31, 1982, Commission File No. 0-9478)

3.3               Bylaws of Registrant (incorporated by reference to Exhibit 4.2
                  filed with Registrant's Registration Statement on Form S-2,
                  Registration No. 2-68999)

3.4               Amendment to Article III, section 2 of Registrant's Bylaws
                  (incorporated by reference to Exhibit 3.3 filed with
                  Registrant's Report on Form 10-K for the fiscal year ended May
                  31, 1982, Commission File No. 0-9478)

3.5               Amendment to Article IV, Section 6 and Section 7 of the
                  Registrant's Bylaws (incorporated by reference to Exhibit 3.4
                  filed with Registrant's Report on Form 10-K for the fiscal
                  year ended May 31, 1982, Commission File No. 0-9478)

3.6               Articles of Amendment to Registrant's Articles of
                  Incorporation increasing authorized stock to 25,000,000 shares
                  (incorporated by reference to Registrant's Schedule 14C-2
                  Information Statement, Exhibit A, filed with the Commission on
                  October 19, 1996, Commission File No. 0-9478)

3.7               Certificate of Ownership of Microgon into Spectrum
                  Laboratories (incorporated by reference to Exhibit 2B to the
                  Registrant's Form 8-K/A on October 15, 1996, Commission File
                  No. 0-9478)

3.8               Reorganization Agreement, dated September 30, 1998, between
                  Spectrum Laboratories, Inc., and Spectrum Medical Industries,
                  Inc. (incorporated by reference to Exhibit 2 to the
                  Registrant's Form 8-K/A filed November 18, 1998, Commission
                  File No. 0-9478)

10.1              Amendment to Investment and Loan Agreement dated August 1,
                  1995 among the Company, Microgon and certain preferred
                  shareholders of Microgon (incorporated by reference to Exhibit
                  2A to the Registrant's Form 8K/A filed on October 15, 1995,
                  Commission File No. 0-9478)

10.2              Stock Option Plan adopted October 11, 1996 (incorporated by
                  reference to Exhibit B to Registrant's filing of Schedule
                  14-2, filed with the Commission on October 9, 1996)

10.3              Registrant's purchase agreement of Cellco, Inc. (incorporated
                  by reference to Exhibit 10.14 with Registrant's Form 8-K dated
                  November 1, 1996, Commission File No. 0-9478) 10.4 Credit
                  agreement, dated as of December 22, 1998, between Registrant
                  and City National Bank (incorporated by reference to Exhibit
                  10.18 filed with Registrant's report on Form 10-KSB for fiscal
                  year ended January 2, 1999, Commission File No. 0-9478)

10.5              Incentive Agreement dated August 10, 1998, between Spectrum
                  Medical Industries, Inc., the Registrant and F. Jesus Martinez
                  and Roy T. Eddleman (incorporated by reference to Exhibit
                  10.19 filed with Registrant's report on Form 10-KSB for fiscal
                  year ended January 2, 1999, Commission File No. 0-9478)


                                       11
<PAGE>

10.6              Sublease agreement dated January 19, 1999 between Millipore
                  Corporation and Spectrum Laboratories, Inc. (incorporated by
                  reference to Exhibit 10.20 filed with Registrant's report on
                  Form 10-KSB for fiscal year ended January 1, 2000, Commission
                  File No. 0-9478)

10.7              First amendment, dated July 14, 1999, to the credit agreement,
                  dated December 22, 1998, between the Company and City National
                  Bank (incorporated by reference to Exhibit 10.21 filed with
                  Registrant's report on Form 10-KSB for fiscal year ended
                  January 1, 2000, Commission File No. 0-9478)

10.8              Second amendment, dated July 1, 2000, to the credit agreement,
                  dated December 22, 1998, between the Company and City National
                  Bank (incorporated by reference to Exhibit 10.8 filed with
                  Registrant's report on Form 10-KSB for fiscal year ended
                  December 30, 2000, Commission File No. 0-9478)

10.9              The Registrant's Year 2000 Stock Option Plan (incorporated by
                  reference to Exhibit 10.9 filed with Registrant's report on
                  Form 10-KSB for fiscal year ended December 30, 2000,
                  Commission File No. 0-9478)

10.10             Third amendment, dated January 8, 2001, to the credit
                  agreement, dated December 22, 1998, between the Company and
                  City National Bank (incorporated by reference to Exhibit 10.10
                  filed with Registrant's report on Form 10-KSB for fiscal year
                  ended December 30, 20010 Commission File No. 0-9478)

10.11             Royalty Agreement, dated June 1, 1976, between Roy T. Eddleman
                  and Spectrum Medical Industries (incorporated by reference to
                  Exhibit 10.11 filed with Registrant's report on Form 10-KSB
                  for fiscal year ended December 30, 2000, Commission File No.
                  0-9478)

10.12             Fourth amendment, dated December 14, 2001, to the credit
                  agreement, dated December 22, 1998, between the Company and
                  City National Bank (incorporated by reference to Exhibit 10.12
                  filed with Registrant's report on Form 10-KSB for fiscal year
                  ended December 29, 2001, Commission File No. 0-9478)

16                Letter on change in certifying accountant (incorporated by
                  reference to Exhibit 16 filed with Registrant's report on Form
                  10-KSB for fiscal year ended January 2, 1999, Commission File
                  No. 0-9478)

99.1              Certification of Chief Executive Officer of Spectrum
                  Laboratories, Inc. (incorporated by reference to Exhibit 99.1
                  filed with Registrant's report on Form 10-QSB for the
                  quarterly period ended June 29, 2002, Commission File No.
                  0-9478)

99.2              Certification of Chief Financial Officer of Spectrum
                  Laboratories, Inc. (incorporated by reference to Exhibit 99.2
                  filed with Registrant's report on Form 10-QSB for the
                  quarterly period ended June 29, 2002, Commission File No.
                  0-9478)

99.3              Certification of Chief Financial Officer of Spectrum
                  Laboratories, Inc.

99.4              Certification of Chief Executive Officer of Spectrum
                  Laboratories, Inc.


(b) The Company filed no reports on Form 8-K during the quarter ended September
28, 2002.


                                       12
<PAGE>


SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized, on November 12, 2002.

SPECTRUM LABORATORIES, INC.
(Registrant)




/s/  F. Jesus Martinez
----------------------------
Signature

F. Jesus Martinez
President





 /s/  Brian A. Watts
----------------------------
Signature

Brian A. Watts
Chief Financial Officer/Vice President of Finance











                                       13
<PAGE>

Certifications

Chief Financial Officer

I, Brian A. Watts Chief Financial Officer certify that:

1.     I have reviewed this quarterly report on Form 10-QSB of Spectrum
       Laboratories, Inc.;

2.     Based on my knowledge, this quarterly report does not contain any untrue
       statement of a material fact or omit to state a material fact necessary
       to make the statements made, in light of the circumstances under which
       such statements were made, not misleading with respect the period covered
       by this quarterly report;

3.     Based on my knowledge, the financial statements, and other financial
       information included in this quarterly report, fairly present in all
       material respects the financial condition, results of operations and cash
       flows of the registrant as of, and for, the periods presented in this
       quarterly report;

4.     The registrant's other certifying officers and I are responsible for
       establishing and maintaining disclosure controls and procedures (as
       defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and
       we have:

       a)     designed such disclosure controls and procedures to ensure that
              material information relating to the registrant, including its
              consolidated subsidiaries, is made known to us by others within
              those entities, particularly during the period in which this
              quarterly report is being prepared; and

       b)     evaluated the effectiveness of the registrant's disclosure
              controls and procedures as of a date within 90 days prior to the
              filing date of this quarterly report ("Evaluation Date"); and

       c)     presented in this quarterly report our conclusions about the
              effectiveness of the disclosure controls and procedures based on
              our evaluation as of the Evaluation Date;

5.     The registrant's other certifying officers and I have disclosed, based on
       our most recent evaluation, to the registrant's auditors and the audit
       committee of registrant's board of directors:

       a)     all significant deficiencies in the design or operation of
              internal controls which could adversely affect the registrant's
              ability to record, process, summarize and report financial data
              and have identified for the registrant's auditors any material
              weaknesses in internal controls; and

       b)     any fraud, whether or not material, that involves management or
              other employees who have a significant role in the registrant's
              internal controls;

6.     The registrant's other certifying officers and I have indicated in this
       quarterly report whether or not there were any significant changes in
       internal controls or in other factors that could significantly affect
       internal controls subsequent to the date of our most recent evaluation,
       including any corrective actions with regard to significant deficiencies
       and material weaknesses.

Dated: November 12, 2002



/s/  Brian A. Watts
Signature

Brian A. Watts
Chief Financial Officer/Vice President of Finance



<PAGE>


Chief Executive Officer

I, Roy T. Eddleman Chief Executive Officer certify that:

1.     I have reviewed this quarterly report on Form 10-QSB of Spectrum
       Laboratories, Inc.;

2.     Based on my knowledge, this quarterly report does not contain any untrue
       statement of a material fact or omit to state a material fact necessary
       to make the statements made, in light of the circumstances under which
       such statements were made, not misleading with respect the period covered
       by this quarterly report;

3.     Based on my knowledge, the financial statements, and other financial
       information included in this quarterly report, fairly present in all
       material respects the financial condition, results of operations and cash
       flows of the registrant as of, and for, the periods presented in this
       quarterly report;

4.     The registrant's other certifying officers and I are responsible for
       establishing and maintaining disclosure controls and procedures (as
       defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and
       we have:

       a)   designed such disclosure controls and procedures to ensure that
            material information relating to the registrant, including its
            consolidated subsidiaries, is made known to us by others within
            those entities, particularly during the period in which this
            quarterly report is being prepared; and

       b)   evaluated the effectiveness of the registrant's disclosure controls
            and procedures as of a date within 90 days prior to the filing date
            of this quarterly report ("Evaluation Date"); and

       c)   presented in this quarterly report our conclusions about the
            effectiveness of the disclosure controls and procedures based on our
            evaluation as of the Evaluation Date;

5.     The registrant's other certifying officers and I have disclosed, based on
       our most recent evaluation, to the registrant's auditors and the audit
       committee of registrant's board of directors:

       a)   all significant deficiencies in the design or operation of internal
            controls which could adversely affect the registrant's ability to
            record, process, summarize and report financial data and have
            identified for the registrant's auditors any material weaknesses in
            internal controls; and

       b)   any fraud, whether or not material, that involves management or
            other employees who have a significant role in the registrant's
            internal controls;

6.     The registrant's other certifying officers and I have indicated in this
       quarterly report whether or not there were any significant changes in
       internal controls or in other factors that could significantly affect
       internal controls subsequent to the date of our most recent evaluation,
       including any corrective actions with regard to significant deficiencies
       and material weaknesses.

Dated: November 12, 2002



/s/  Roy T. Eddleman
Signature

Roy T. Eddleman
Chief Executive Officer & Chairman